InvestorsHub Logo

BottomBounce

10/19/19 6:32 PM

#21044 RE: Drugdoctor #21035

$CVSI CV Sciences’ Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions.
https://cvsciences.com/about-us/